Tavokinogene telseplasmid

N/A

Report date: 2024/09/19 15:13:38

Base Information

Drug NameTavokinogene telseplasmid
Drug Alias NameImmunopulseIL-12-gene-therapy-InovioInterleukin-12 gene therapyIL-12 gene therapyInterleukin-12 gene therapy (OncoSec Medical) +[9] 
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionImmunostimulantsGene transferenceInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsProstatic NeoplasmsTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSirtex Medical Pty LtdH Lee Moffitt Cancer Center & Research InstituteOncosec Medical Incorporated
Inactive CompaniesUniversity Of California San FranciscoInovio Pharmaceuticals IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsTriple Negative Breast NeoplasmsMelanoma
Inactive IndicationsProstatic NeoplasmsSquamous Cell Carcinoma of Head and NeckMycosis Fungoides +[9] 

Other Information

ATC CodeN/A
Related LinksN/A